| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.043 | 0.4 |
| mRNA | Salubrinal | GDSC1000 | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |